About Us
Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them. Our heritage of being a provider of generic pharmaceuticals goes back to our founding in West Virginia in 1961. Today, we are passionate champions for better health around the world with a platform unmatched in the industry.
We have one of the broadest and most diverse portfolios, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products. Our healthcare services help patients to access products and adhere to medication regimens to help promote better health outcomes.
We now offer products in more than 165 countries and territories. And depending on the market, our products are distributed through retail channels, by healthcare professionals or in institutional settings.
We have a strong track record of developing new products, particularly complex and difficult-to-formulate medicines. Our approximately 50 plants around the world manufacture tens of billions of doses of medicine annually, and each site adheres to stringent quality standards, regardless of location.
Our most valuable asset is our global workforce, each member of which is a passionate supporter of our cause to deliver better health for a better world.
History
Explore more than 50 years of unconventional success.
-
0
Day 1
First known as Milan, the company starts doing business in White Sulphur Springs, West Virginia. U.S. Army buddies, Milan "Mike" Puskar and Don Panoz flip a coin to see who will name the business and who will be the company’s first president. They start distributing products to doctors and pharmacists from an old Pontiac Bonneville. -
0
-
0
Our First Medicine
After receiving approval from the U.S. Food and Drug Administration to manufacture our first medicine, Penicillin G, we broaden our product line to include other generic antibiotics as well as analgesics, antihistamines, diuretics and tranquilizers. We market these to large drug companies, drug store chains and mail-order drug providers, all for resale under the customers’ own labels.
-
0
-
0
-
0
-
0
-
0
GPIA and Hatch-Waxman
Mike Puskar helps establish the Generic Pharmaceutical Industry Association, GPIA, to give the industry a voice. During the next few years, GPIA lobbies for the Hatch-Waxman Act, which passes in 1984.
-
0
First to Market
Our first branded product approval, for MAXZIDE® TABLETS (triamterene and hydrocholorothiazide tablets, US), is a first for a generics company.
-
0
Doing What’s Right, Not What’s Easy
We see irregularities in how the FDA acts on abbreviated new drug applications. Our investigation helps expose fraudulent practices and corruption in the industry. This results in reform of the FDA’s review procedures for generic drugs and new precautions to help ensure consumer safety.
-
0
Diversification
The market is becoming increasingly competitive as demand for high quality, affordable medication rises.
- In 1993, we acquire Bertek Inc., an innovator of transdermal medicine systems. Bertek is later renamed Mylan Technologies Inc., or MTI
- In 1996, Mylan adds unit dose packaging with the acquisition of UDL, the largest pharmaceutical unit dose packaging company in the U.S.
- At the same time, generic use rises to about 47%, and we continue to capture market share while discontinuing private labeling and growing our own “Mylan” label
-
0
-
0
-
0
-
0
-
0
-
0
Organic Growth
In the U.S., the Medicare Prescription Drug, Improvement and Modernization Act and an aging Medicare population fuel generic utilization, which reaches 78% by decade’s end. We are ready, having put in place a plan to expand through organic growth and acquisitions from a mid-size company into a global leader.
-
0
-
0
Going Global
We become a global company by acquiring a controlling interest in Matrix Laboratories and by purchasing Merck KGaA’s generics business.
- In addition to being a supplier of active pharmaceutical ingredients (API), Matrix has low-cost manufacturing facilities in India and China and marketing capabilities in Western Europe and Africa. Matrix gives us unprecedented control over our supply chain and expands our dosage forms and therapeutic categories. This includes the addition of antiretroviral medicines for people living with HIV/AIDS
- Merck KGaA’s generic business sells products in more than 90 countries. Combining forces provides massive global scale, expands our product portfolio and provides entry into new commercial markets
- With the acquisition of Merck KGaA generic business, we acquire the rights to EpiPen® (epinephrine injection, USP) Auto-Injector, the world's No. 1 dispensed epinephrine auto-injector* *IMS data, 1987-2012
-
0
-
0
Global Leadership
- Mike Puskar retires and Robert J. Coury is named chairman of the board.
- We launch next-generation EpiPen® (epinephrine injection, USP) Auto-Injector.
- Our first global product, LANSOPRAZOLE (lansoprazole capsule, delayed release pellets), launches.
- Lopinavir/Ritonavir, an innovative heat-stable ARV treatment, is created for use in certain countries where refrigeration isn't readily available.
- Robert J. Coury and former President Bill Clinton announce an agreement for better, more affordable treatment for HIV/AIDS patients in the developing world.
- Mylan and Biocon partner to enter the global generics biologics market.
-
0
Bioniche Pharma
Our acquisition of Bioniche Pharma expands our injectable portfolio with products for use in orthopaedics, rheumatology, urology and dermatology.
-
0
-
0
Championing National Policy
Mylan, led by Heather Bresch, champions the Food and Drug Administration Safety and Innovation Act (FDASIA), which holds both foreign and domestic manufacturers to one global quality standard. The Act includes the Generic Drug User Fee Act (GDUFA). Together, FDASIA and GDUFA aim to speed up access to safe and effective generic medicines while providing more visibility into how medicines and their ingredients are manufactured and shipped around the world.
-
0
-
0
-
0
Ongoing Global Leadership
- Our antiretroviral portfolio launches in South Africa
- EpiPen® (epinephrine injection, USP) Auto-Injector celebrates 25 years as the No. 1 prescribed epinephrine auto-injector in the U.S.*
- Mylan acquires Agila Specialties creating a global injectables leader
- Expands partnership with Biocon for portfolio of insulin analogs
- Acquires respiratory assets from Pfizer *IMS data, 1987-2012
-
0
-
0
-
0
-
0
At Mylan, we are committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we:
- Innovate to satisfy unmet needs
- Make reliability and service excellence a habit
- Do what’s right, not what’s easy
- Impact the future through passionate global leadership


We are unconventional, visionary and bold. We “connect the dots” others overlook. We see possibilities and bring them to life. We love to challenge the status quo and introduce new and better ways to help people everywhere enjoy a higher quality of life. Having the courage to be a force for constructive change is in our DNA.
Doing what's right is sacred to us. We behave responsibly, even when nobody's looking. We set high standards from which we never back down. This uncompromising ethical stance helps to keep our products pure, our workers safe and the environment clean.
Dependable. Reliable. Call it what you will, we've made it a habit. We strive to be there through thick and thin, rain or shine, delivering on every promise, every time. That's why people around the corner and across the world count on Mylan.
We understand that "it's not about us"—it's about helping others—and we believe there's no situation we can't handle. We would do whatever it takes, work ‘round the clock, cross any river and spare no effort—all to meet someone’s need. We wrap our high quality products in high quality service.
Together, we can run faster, reach higher and achieve more than any one of us can alone. We relish opportunities to collaborate because it’s invigorating, enlightening and powerful. When we join forces and plow through boundaries, we move mountains.
1961: Year founded in White Sulphur Springs, West Virginia, U.S.
~7 billion: People we work to provide with access to high quality medicine
>165: Countries and territories in which our products are sold
>7,500: Separate products currently being marketed
80 billion: Oral solid dose capacity
>35,000: Workforce